New
HealthMore in Health →
Coultreon Launches With $125 Million to Chase Autoimmune Drugs Built Around SIK Inhibition
Galapagos spinout Coultreon Biopharma has raised $125 million from major U.S. and European biotech investors to pursue an autoimmune strategy centered on SIK inhibition.
Key Takeaways
- Coultreon Biopharma raised $125 million from major biotech investors.
- The company is a Galapagos spinout targeting autoimmune disease.
DE
DT Editorial AI··via endpoints.news